Man Group plc acquired a new position in ASP Isotopes Inc. (NASDAQ:ASPI - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 828,377 shares of the company's stock, valued at approximately $5,153,000. Man Group plc owned approximately 0.54% of ASP Isotopes at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently modified their holdings of ASPI. Quantbot Technologies LP bought a new position in ASP Isotopes in the 3rd quarter worth $34,000. BNP Paribas Financial Markets raised its holdings in ASP Isotopes by 84.9% during the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company's stock valued at $41,000 after acquiring an additional 2,548 shares during the period. State of Wyoming purchased a new position in shares of ASP Isotopes in the first quarter valued at about $29,000. Allworth Financial LP bought a new position in shares of ASP Isotopes in the second quarter worth about $51,000. Finally, Legal & General Group Plc boosted its stake in shares of ASP Isotopes by 30.4% in the third quarter. Legal & General Group Plc now owns 8,377 shares of the company's stock worth $81,000 after acquiring an additional 1,953 shares during the period. 16.80% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other news, CEO Paul Elliot Mann sold 83,759 shares of the business's stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $7.76, for a total value of $649,969.84. Following the sale, the chief executive officer directly owned 9,579,845 shares in the company, valued at $74,339,597.20. The trade was a 0.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Robert Ainscow sold 8,438 shares of the business's stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $7.00, for a total value of $59,066.00. Following the sale, the chief operating officer directly owned 2,281,879 shares in the company, valued at $15,973,153. The trade was a 0.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 279,079 shares of company stock worth $2,049,208. Insiders own 14.40% of the company's stock.
Analysts Set New Price Targets
Several analysts recently issued reports on the company. Wall Street Zen raised ASP Isotopes from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of ASP Isotopes in a research note on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $13.00.
Read Our Latest Analysis on ASP Isotopes
ASP Isotopes Stock Performance
NASDAQ:ASPI opened at $3.88 on Monday. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.87 and a quick ratio of 3.85. ASP Isotopes Inc. has a 1 year low of $3.51 and a 1 year high of $14.49. The stock's 50 day simple moving average is $4.66 and its two-hundred day simple moving average is $5.25. The company has a market cap of $594.84 million, a price-to-earnings ratio of -2.94 and a beta of 3.61.
ASP Isotopes (NASDAQ:ASPI - Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.11). ASP Isotopes had a negative net margin of 427.98% and a negative return on equity of 64.99%. The firm had revenue of $5.12 million for the quarter, compared to the consensus estimate of $4.47 million.
ASP Isotopes Profile
(
Free Report)
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ASP Isotopes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ASP Isotopes wasn't on the list.
While ASP Isotopes currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.